Oxford Nanopore reported 2025 revenue of £223.9 million, a 22% year‑over‑year increase, and detailed a strategic restructuring that included job reductions and a narrower product focus. The company will discontinue active sales of the ElysIon platform, phase out the PromethIon 2 Solo, and concentrate investment on its highest‑priority offerings. Management said the reorganization simplifies the portfolio, reallocates R&D to core opportunities, and grows production headcount to meet demand. Restructuring costs totaled £22.6 million. The shift signals Oxford Nanopore’s move to prioritize sustainable commercial growth over broad product diversification, with implications for clinical and biopharma customers who relied on the discontinued platforms and for competitors in the sequencing market.